Click to toggle navigation menu.

Press Releases

Onkos Surgical® Announces 500th NanoCept® Case Utilizing ELEOS™ Limb Salvage System

Milestone highlights continued adoption of antibacterial implant technology in complex orthopaedic procedures PARSIPPANY, N.J., June 29, 2026 /PRNewswire/ — Onkos Surgical, a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic conditions, today announced the completion of the 500th case utilizing its NanoCept® Antibacterial Technology on the ELEOS™ Limb Salvage System. Since receiving De Novo...
Learn More

Onkos Surgical® Receives FDA 510(k) Clearance for Application of NanoCept® Antibacterial Technology to Titanium Implants in the ELEOS™ Limb Salvage System

Parsippany, NJ — June 8, 2026 — Onkos Surgical, a leader in innovative solutions for musculoskeletal oncology and complex orthopaedic conditions, today announced it has received clearance from the U.S. Food and Drug Administration (FDA) for the application of its NanoCept Antibacterial Technology on titanium implants within the ELEOS Limb...
Learn More

Built to Heal, Designed to Defend.

In a recent Orthopedic Design & Technology Q&A, Onkos Surgical Founder & CEO Patrick Treacy shares how patient-specific design, 3D printing, and antibacterial innovation are shaping the future of complex orthopaedic care—including strategies to help address bacterial contamination in high-risk procedures with NanoCept®, the first FDA-granted antibacterial technology for orthopaedic...
Learn More

Onkos Surgical® Announces Initiation of 522 Post-Market Surveillance Study of the ELEOS™ Limb Salvage System with NanoCept® Antibacterial Implant Technology

PARSIPPANY, N.J., Feb. 12, 2026 /PRNewswire/ -- Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures, today announced the enrollment of the first patient in its Post-Market Surveillance Study of the ELEOS Limb Salvage System with NanoCept Antibacterial Implant Technology. This first and only orthopaedic antibacterial coating technology available on...
Learn More

Onkos NanoCept™ Antibacterial technology featured in BoneZone

Checking in on Exciting Advancements in Antimicrobial Implants by Dan Cook on Nov 26, 2024 There’s no doubt that infections related to contaminated orthopedic implants are serious complications that need to be addressed. However, industry stakeholders might not fully grasp the troubling extent of the issue. Patrick Treacy, Founder and CEO of...
Learn More

Onkos Surgical® Successfully Completes Groundbreaking, First-in-Human Cases Using NanoCept™ Antibacterial Technology

Parsippany, NJ – January 9, 2025 – Onkos Surgical, a leading provider of innovative solutions for complex orthopaedic procedures, today announced that its revolutionary NanoCept Antibacterial Technology has been used successfully in multiple surgical procedures. NanoCept is a novel antibacterial coating applied to orthopaedic implants to help address intraoperative bacterial...
Learn More

Horizon Technology Finance Provides $35 Million Venture Loan Facility to Onkos Surgical® to Accelerate Commercialization of Novel Antibacterial Implant Technology

Farmington, Connecticut – January 8, 2025 – Horizon Technology Finance Corporation (NASDAQ: HRZN) (“Horizon” or the “Company”), an affiliate of Monroe Capital, and a leading specialty finance company that provides capital in the form of secured loans to venture capital-backed companies in the technology, life science, healthcare information and services,...
Learn More

Onkos Surgical Announces First FDA De Novo Approval of an Antibacterial Coating for Tumor and Revision Orthopaedic Implants

Bacterial contamination of orthopaedic implants is a growing clinical challenge that burdens the healthcare system and can lead to dangerous, potentially fatal complications for patients. PARSIPPANY, N.J., April 8, 2024 /PRNewswire/ -- Onkos Surgical, an orthopaedic company founded to address the complex clinical challenges associated with bone loss due to tumor,...
Learn More